JP3528186B2 - 光学活性キノリンメバロン酸のジアステレオマー塩 - Google Patents
光学活性キノリンメバロン酸のジアステレオマー塩Info
- Publication number
- JP3528186B2 JP3528186B2 JP12727792A JP12727792A JP3528186B2 JP 3528186 B2 JP3528186 B2 JP 3528186B2 JP 12727792 A JP12727792 A JP 12727792A JP 12727792 A JP12727792 A JP 12727792A JP 3528186 B2 JP3528186 B2 JP 3528186B2
- Authority
- JP
- Japan
- Prior art keywords
- optically active
- quinoline
- mevalonic acid
- acid
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title claims description 85
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 title claims description 40
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 title claims description 39
- 150000003839 salts Chemical class 0.000 title claims description 22
- 238000000034 method Methods 0.000 claims abstract description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- 230000003287 optical effect Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 1
- KFPZNZVASUJWQQ-AWKYBWMHSA-N C1=CC=CC2=NC(C(O)C[C@](O)(C)CC(O)=O)=CC=C21 Chemical compound C1=CC=CC2=NC(C(O)C[C@](O)(C)CC(O)=O)=CC=C21 KFPZNZVASUJWQQ-AWKYBWMHSA-N 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 14
- -1 quinoline mevalonic acid derivative Chemical class 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical compound C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 description 4
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- RWNJOXUVHRXHSD-UHFFFAOYSA-N hept-6-enoic acid Chemical compound OC(=O)CCCCC=C RWNJOXUVHRXHSD-UHFFFAOYSA-N 0.000 description 4
- 229940057061 mevalonolactone Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229910052987 metal hydride Inorganic materials 0.000 description 3
- 150000004681 metal hydrides Chemical class 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 150000007934 α,β-unsaturated carboxylic acids Chemical class 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JCBPETKZIGVZRE-SCSAIBSYSA-N (2r)-2-aminobutan-1-ol Chemical compound CC[C@@H](N)CO JCBPETKZIGVZRE-SCSAIBSYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-QMMMGPOBSA-N (R)-(-)-2-Phenylglycinol Chemical compound OC[C@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-QMMMGPOBSA-N 0.000 description 1
- SOZMSEPDYJGBEK-UHFFFAOYSA-N 1-(4-bromophenyl)ethanamine Chemical compound CC(N)C1=CC=C(Br)C=C1 SOZMSEPDYJGBEK-UHFFFAOYSA-N 0.000 description 1
- UZDDXUMOXKDXNE-UHFFFAOYSA-N 1-(4-methylphenyl)ethanamine Chemical compound CC(N)C1=CC=C(C)C=C1 UZDDXUMOXKDXNE-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001617 alkaline earth metal chloride Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FESAXEDIWWXCNG-UHFFFAOYSA-N diethyl(methoxy)borane Chemical compound CCB(CC)OC FESAXEDIWWXCNG-UHFFFAOYSA-N 0.000 description 1
- IPLQYBKTRGYIDX-UHFFFAOYSA-N ethanol;4-methylpentan-2-one Chemical compound CCO.CC(C)CC(C)=O IPLQYBKTRGYIDX-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- KWHDXJHBFYQOTK-UHFFFAOYSA-N heptane;toluene Chemical compound CCCCCCC.CC1=CC=CC=C1 KWHDXJHBFYQOTK-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- NBRTVBSAFSYLEE-UHFFFAOYSA-N n,n-dimethylformamide;4-methylpentan-2-one Chemical compound CN(C)C=O.CC(C)CC(C)=O NBRTVBSAFSYLEE-UHFFFAOYSA-N 0.000 description 1
- ZYZHMSJNPCYUTB-UHFFFAOYSA-N n-benzyl-1-phenylethanamine Chemical compound C=1C=CC=CC=1C(C)NCC1=CC=CC=C1 ZYZHMSJNPCYUTB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical class C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- LALRXNPLTWZJIJ-UHFFFAOYSA-N triethylborane Chemical compound CCB(CC)CC LALRXNPLTWZJIJ-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12727792A JP3528186B2 (ja) | 1991-06-24 | 1992-05-20 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
| TW081104622A TW293007B (enExample) | 1991-06-24 | 1992-06-12 | |
| CA002072162A CA2072162C (en) | 1991-06-24 | 1992-06-23 | Diastereomer salt of optically active quinolinemevalonic acid |
| US07/902,863 US5284953A (en) | 1991-06-24 | 1992-06-23 | Diastereomer salt of optically active quinolinemevalonic acid |
| EP96107815A EP0742209A3 (en) | 1991-06-24 | 1992-06-24 | Process for the preparation of an optically active quinoline demevalonolacton and process for the preparation of a salt of an optically active quinoline demevalolon |
| DE69226822T DE69226822T2 (de) | 1991-06-24 | 1992-06-24 | Diastereomeres Salz von optisch aktiver Chinolinmevalonsäure |
| KR1019920011018A KR100208867B1 (ko) | 1991-06-24 | 1992-06-24 | 광학활성 퀴놀린메발론산의 디아스테레오머염 |
| EP92110636A EP0520406B1 (en) | 1991-06-24 | 1992-06-24 | Diastereomer salt of optically active quinolinemevalonic acid |
| AT92110636T ATE170513T1 (de) | 1991-06-24 | 1992-06-24 | Diastereomeres salz von optisch aktiver chinolinmevalonsäure |
| ES92110636T ES2120973T3 (es) | 1991-06-24 | 1992-06-24 | Sal de diastereomero de acido quinolinmevalonico opticamente activo. |
| DK92110636T DK0520406T3 (da) | 1991-06-24 | 1992-06-24 | Diastereomert salt af optisk aktiv quinolinmevalonsyre |
| US08/123,117 US5473075A (en) | 1991-06-24 | 1993-09-20 | Diastereomer salt of optically active quinolinemevalonic acid |
| US08/450,383 US5514804A (en) | 1991-06-24 | 1995-05-25 | Diastereomer salt of optically active quinolinemevalonic acid |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3-151810 | 1991-06-24 | ||
| JP15181091 | 1991-06-24 | ||
| JP12727792A JP3528186B2 (ja) | 1991-06-24 | 1992-05-20 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH05148237A JPH05148237A (ja) | 1993-06-15 |
| JP3528186B2 true JP3528186B2 (ja) | 2004-05-17 |
Family
ID=26463266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12727792A Expired - Lifetime JP3528186B2 (ja) | 1991-06-24 | 1992-05-20 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US5284953A (enExample) |
| EP (2) | EP0520406B1 (enExample) |
| JP (1) | JP3528186B2 (enExample) |
| KR (1) | KR100208867B1 (enExample) |
| AT (1) | ATE170513T1 (enExample) |
| CA (1) | CA2072162C (enExample) |
| DE (1) | DE69226822T2 (enExample) |
| DK (1) | DK0520406T3 (enExample) |
| ES (1) | ES2120973T3 (enExample) |
| TW (1) | TW293007B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1136183C (zh) * | 1994-02-25 | 2004-01-28 | 代科化学工业株式会社 | 光学活性甲羟戊酸内酯类化合物的制造方法 |
| BR9609872A (pt) | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
| DK0814782T3 (da) * | 1995-12-22 | 2002-12-16 | Nissan Chemical Ind Ltd | Farmaceutisk præparat stabiliseret med et basisk middel |
| GB9614804D0 (en) * | 1996-07-15 | 1996-09-04 | Chiroscience Ltd | Resolution process |
| AU755543B2 (en) * | 1997-12-19 | 2002-12-12 | Warner-Lambert Export Limited | Process for the synthesis of 1,3-diols |
| PT1099694E (pt) | 1998-07-23 | 2005-10-31 | Nissan Chemical Ind Ltd | Processo para a preparacao de um derivado de quinolina e um intermediario para esse fim |
| KR100311645B1 (ko) * | 1999-12-24 | 2001-10-12 | 이홍천 | 간판 |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| AU2002241271B2 (en) * | 2001-04-05 | 2007-01-25 | Nissan Chemical Industries, Ltd. | Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate |
| JP4783998B2 (ja) * | 2001-05-15 | 2011-09-28 | 宇部興産株式会社 | （３ｒ，５ｓ）−７−置換−３，５−ジヒドロキシヘプト−６−エン酸の製法 |
| WO2003027073A1 (fr) * | 2001-09-19 | 2003-04-03 | Ube Industries, Ltd. | Procede de production d'ester optiquement actif d'acide 7-{2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl}-3,5-dihydroxyhept-6-enoique |
| US6835838B2 (en) * | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
| DE60326819D1 (de) | 2002-01-31 | 2009-05-07 | Novartis Ag | Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase |
| ZA200502325B (en) | 2002-09-20 | 2006-11-29 | Nissan Chemical Ind Ltd | Method for producing a 3,5-dihydroxy-6-heptenoate |
| WO2004072040A1 (en) * | 2003-02-12 | 2004-08-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of pitavastatin calcium |
| EP1614429A4 (en) * | 2003-04-17 | 2007-05-02 | Kowa Co | LKLF / KLF2 GEN-EXPRESSIONSPROMOTER |
| WO2005077916A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
| JP2007512347A (ja) * | 2003-11-26 | 2007-05-17 | デューク・ユニバーシティー | 緑内障を予防するかまたは治療する方法 |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| CN101220021B (zh) * | 2007-01-12 | 2010-12-08 | 上海医药工业研究院 | 4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用 |
| WO2008111055A1 (en) * | 2007-03-12 | 2008-09-18 | In-Dot Ltd. | Color sensing for a reader device and the like |
| WO2010027060A1 (ja) * | 2008-09-05 | 2010-03-11 | 日産化学工業株式会社 | ３，５－ジヒドロキシ－６－ヘプテン酸アミン塩類の製造方法 |
| US20120022102A1 (en) | 2010-01-20 | 2012-01-26 | Cadila Healthcare Limited | Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof |
| JP2013536219A (ja) | 2010-08-25 | 2013-09-19 | カディラ・ヘルスケア・リミテッド | ピタバスタチンカルシウムおよびその調製方法 |
| WO2012063254A1 (en) * | 2010-11-12 | 2012-05-18 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
| KR101270586B1 (ko) * | 2010-11-26 | 2013-06-03 | 주식회사 아미노로직스 | 광학적으로 순수한 2,2'-디히드록시-1,1'-바이나프틸-3-카르복실산의 제조방법 |
| WO2012140490A2 (en) | 2011-04-11 | 2012-10-18 | Aurobindo Pharma Limited | Process for preparing quinoline derivative |
| JP2011173912A (ja) * | 2011-04-28 | 2011-09-08 | Ube Industries Ltd | （３ｒ，５ｓ）−７−置換−３，５−ジヒドロキシヘプト−６−エン酸の製法 |
| WO2013037838A1 (en) | 2011-09-12 | 2013-03-21 | Farma Grs, D.O.O. | Polymorphic form of pitavastatin calcium |
| JP2013103884A (ja) * | 2011-11-10 | 2013-05-30 | Daito Kk | ピタバスタチンカルシウム塩の工業的製造方法 |
| CN102653523A (zh) * | 2011-12-17 | 2012-09-05 | 东莞达信生物技术有限公司 | 一种匹伐他汀钙重结晶制取方法 |
| WO2013098773A1 (en) * | 2011-12-28 | 2013-07-04 | Dr. Reddy's Laboratories Limited | Crystalline forms of pitavastatin calcium |
| CN102653524A (zh) * | 2012-01-12 | 2012-09-05 | 东莞达信生物技术有限公司 | 一种匹伐他汀钙中间体的制备方法 |
| EP2978743B1 (en) * | 2013-03-29 | 2019-11-27 | Centrient Pharmaceuticals Netherlands B.V. | Amine salts of pravastatin and rosuvastatin |
| MX2015013696A (es) * | 2013-03-29 | 2016-02-26 | Dsm Sinochem Pharm Nl Bv | Sales de amina de pitavastatina y rosuvastatina. |
| CN103508949B (zh) * | 2013-10-22 | 2015-12-09 | 黄河三角洲京博化工研究院有限公司 | 一种（e）-3-[2-环丙基-4-（4-氟-苯基）-3-喹啉基]丙烯醛的合成方法 |
| WO2016056658A1 (ja) * | 2014-10-10 | 2016-04-14 | 株式会社エーピーアイ コーポレーション | スタチン系化合物の精製方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3905908A1 (de) | 1989-02-25 | 1990-09-06 | Bayer Ag | Substituierte chinoline, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH576447A5 (enExample) * | 1972-03-10 | 1976-06-15 | Ciba Geigy Ag | |
| US4567289A (en) * | 1979-08-17 | 1986-01-28 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
| CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| DE3925636A1 (de) * | 1989-08-03 | 1991-02-07 | Bayer Ag | Imino-substituierte pyridine |
| EP0430129A3 (en) * | 1989-11-30 | 1992-02-26 | Tanabe Seiyaku Co., Ltd. | Novel phenylethylene derivatives, processes for preparing the same and intermediates therefor |
| JPH054943A (ja) * | 1990-08-30 | 1993-01-14 | Sagami Chem Res Center | 光学活性β，δ−ジケト酸エステル及びその還元体 |
-
1992
- 1992-05-20 JP JP12727792A patent/JP3528186B2/ja not_active Expired - Lifetime
- 1992-06-12 TW TW081104622A patent/TW293007B/zh active
- 1992-06-23 CA CA002072162A patent/CA2072162C/en not_active Expired - Lifetime
- 1992-06-23 US US07/902,863 patent/US5284953A/en not_active Expired - Lifetime
- 1992-06-24 DE DE69226822T patent/DE69226822T2/de not_active Expired - Lifetime
- 1992-06-24 AT AT92110636T patent/ATE170513T1/de active
- 1992-06-24 EP EP92110636A patent/EP0520406B1/en not_active Expired - Lifetime
- 1992-06-24 DK DK92110636T patent/DK0520406T3/da active
- 1992-06-24 EP EP96107815A patent/EP0742209A3/en not_active Withdrawn
- 1992-06-24 KR KR1019920011018A patent/KR100208867B1/ko not_active Expired - Lifetime
- 1992-06-24 ES ES92110636T patent/ES2120973T3/es not_active Expired - Lifetime
-
1993
- 1993-09-20 US US08/123,117 patent/US5473075A/en not_active Expired - Lifetime
-
1995
- 1995-05-25 US US08/450,383 patent/US5514804A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3905908A1 (de) | 1989-02-25 | 1990-09-06 | Bayer Ag | Substituierte chinoline, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2072162A1 (en) | 1992-12-25 |
| EP0742209A3 (en) | 1997-05-14 |
| ATE170513T1 (de) | 1998-09-15 |
| EP0520406A1 (en) | 1992-12-30 |
| DK0520406T3 (da) | 1998-12-14 |
| TW293007B (enExample) | 1996-12-11 |
| KR100208867B1 (ko) | 1999-07-15 |
| EP0520406B1 (en) | 1998-09-02 |
| US5473075A (en) | 1995-12-05 |
| JPH05148237A (ja) | 1993-06-15 |
| KR930000486A (ko) | 1993-01-15 |
| US5284953A (en) | 1994-02-08 |
| CA2072162C (en) | 2002-11-19 |
| EP0742209A2 (en) | 1996-11-13 |
| DE69226822T2 (de) | 1999-02-11 |
| DE69226822D1 (de) | 1998-10-08 |
| US5514804A (en) | 1996-05-07 |
| ES2120973T3 (es) | 1998-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH05148237A (ja) | 光学活性キノリンメバロン酸のジアステレオマー塩 | |
| JPS63139182A (ja) | チアゾリジンジオン誘導体の製造法 | |
| US8026377B2 (en) | Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt | |
| KR100978970B1 (ko) | Ｈｍｇ-ｃｏａ 환원효소 저해 메발론산 유도체의 제조방법 | |
| WO2006100689A1 (en) | Process for preparation of rosuvastatin | |
| US7812179B2 (en) | Process for the preparation of atorvastatin and intermediates | |
| US20080161560A1 (en) | Process for Preparation of Calcium Salt of Rosuvastatin | |
| US6278001B1 (en) | Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping | |
| US20030078430A1 (en) | Process for preparing 1,4-dihydropyridine compounds | |
| JPH01165554A (ja) | 置換ヒドロキシルアミン | |
| SK288093B6 (sk) | Novel boronate esters | |
| KR101063146B1 (ko) | 피타바스타틴 중간체의 제조방법 및 이를 이용한 피타바스타틴 헤미 칼슘염의 제조방법 | |
| JP2507163B2 (ja) | 光学活性４―フェニル酪酸エステル誘導体のラセミ化方法 | |
| CN104447784B (zh) | 一种他汀类药物中间体及其制备方法和应用 | |
| CN101107230B (zh) | 5-氯-2,4-二羟基吡啶的制造方法 | |
| FR2792635A1 (fr) | Derives de cyclobutene-3,4-dione leur preparation et leur application en therapeutique | |
| JP4639327B2 (ja) | 光学活性アミノピリジル基含有ピロリジン誘導体及びそれを用いた不斉合成方法 | |
| HUT52047A (en) | Process for producing disubstituted pyrrol derivatives and pharmaceutical compositions containing them | |
| JP3006748B2 (ja) | 光学活性な７−置換ピリジル−３，５−ジヒドロキシ−ヘプト−６−エン酸エステル誘導体の製法 | |
| JPH11209345A (ja) | 医薬品の中間体の製造方法 | |
| JP3770678B2 (ja) | 光学活性アルコール及びそのカルボン酸エステル | |
| KR20050031343A (ko) | 신규한 신·의약 중간체 및 제조방법 | |
| JPWO2006083010A1 (ja) | ４−アセチルピリミジン化合物の製造方法およびその結晶 | |
| JPS6155496B2 (enExample) | ||
| JP2003277324A (ja) | （ｓ）−５−置換−５−ヒドロキシ−３−オキソペンタン酸エステル誘導体の製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040216 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090305 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100305 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110305 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110305 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120305 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130305 Year of fee payment: 9 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130305 Year of fee payment: 9 |